Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene plans restructuring to focus on research and development

20150629 PR 29 juin fin

Published 29 June 2015
Categorized as 2015, Press release

Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)

20150601 PR TG4010 TIME results_ASCO 2015_FINAL

Published 1 June 2015
Categorized as 2015, Press release, TG4010

Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy

Elisabeth Quoix, et al. ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois Download the poster here Poster Presentation

Published 1 June 2015
Categorized as -others, 2015, Publication, TG4010

Transgene Announces Participation at Upcoming Investor Events

20150518 May thru July 2015 IR events_ver 1 ENG

Published 18 May 2015
Categorized as 2015, Press release

TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models

Karine Lélu, et al. Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article Publication

Published 30 April 2015
Categorized as -others, 2015, Publication, TG1050

TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models

Karine Lélu, et al. EASL Liver Congress 2015, Vienna-23th April 2015 Download the poster here Poster Presentation

Published 30 April 2015
Categorized as -others, 2015, Publication, TG1050

Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015

20150423 – US – EASL2015 TG1050

Published 23 April 2015
Categorized as 2015, Press release, TG1050

Transgene Reports First Quarter 2015 Financial Results

20150422 PR US Q1 2015

Published 22 April 2015
Categorized as 2015, Press release

Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody

20150421 AACR 2015_English

Published 21 April 2015
Categorized as 2015, Press release, TG3003, TG4010

Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer

Poster TG4010-AACR 2015-KR Karola Rittner, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497 Download the posterhere Poster Presentation

Published 21 April 2015
Categorized as -others, 2015, Publication, TG4010

Posts pagination

Newer posts Page 1 … Page 44 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu